-
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
Share
- Annual Grants Deepen Takeda’s Commitment to Improving Health Through Community-Based Programs
- Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem
CAMBRIDGE, Mass.--(BUSINESS WIRE)--See the full release at Takeda.com
Contacts
Media Contact:
Takeda Media Relations
media_relations@takeda.com
Takeda Pharmaceutical Company Limited
More News From Takeda Pharmaceutical Company Limited
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to tr...
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance acro...
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a...
